Madrigal Pharmaceuticals Stock Forecast
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 9:39 AM ET
MDGL analyst consensus
Consensus (19 analysts)
strong_buy
Avg. price target
$682.11+40.64%
- Strong buy 3
- Buy 15
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 19 Wall Street analysts covering Madrigal Pharmaceuticals (2026-10-07), 18 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $682.11, with a high estimate of $962.00 and a low estimate of $543.00. The average target implies upside of 40.6% from the current price of $485.00.
The spread between the highest and lowest targets is 77.2%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MDGL.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 16% |
| Buy | 15 | 79% |
| Hold | 1 | 5% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $543.00 | +11.96% |
| Average target | $682.11 | +40.64% |
| High target | $962.00 | +98.35% |